- Trials with a EudraCT protocol (552)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
552 result(s) found for: Experimental drug.
Displaying page 24 of 28.
EudraCT Number: 2009-017591-24 | Sponsor Protocol Number: H8Z-MC-JACW | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fi... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005912-27 | Sponsor Protocol Number: GO27819 | Start Date*: 2012-08-17 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH BEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN PATIEN... | ||||||||||||||||||
Medical condition: Patients with recurrent Glioblastoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016055-22 | Sponsor Protocol Number: Reuma hepA | Start Date*: 2009-11-27 | |||||||||||
Sponsor Name:HY, HUS | |||||||||||||
Full Title: Immuunipuutteisten matkailijoiden A-hepatiittisuojaus | |||||||||||||
Medical condition: Terveet vapaaehtoiset ja vapaaehtoiset potilaat, joilla on diagnosoitu nivelreuma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000100-41 | Sponsor Protocol Number: PN018 | Start Date*: 2018-11-21 | ||||||||||||||||
Sponsor Name:Abide Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder | ||||||||||||||||||
Medical condition: Tourette syndrome or chronic motor tic disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002038-21 | Sponsor Protocol Number: CO40115 | Start Date*: 2018-05-01 | |||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATI... | |||||||||||||
Medical condition: Triple-negative breast cancer (TNBC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011606-41 | Sponsor Protocol Number: CP-MGA031-03 | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in C... | |||||||||||||
Medical condition: Recent-onset type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) NL (Prematurely Ended) ES (Completed) FI (Completed) GB (Completed) DE (Completed) BE (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002329-39 | Sponsor Protocol Number: RE06 | Start Date*: 2018-01-08 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with r... | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003753-33 | Sponsor Protocol Number: 095 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Estudio abierto internacional multicéntrico de vorinostat (MK-0683) en combinación con bortezomib en pacientes con mieloma múltiple recidivante y resistente al tratamiento An International, Multic... | |||||||||||||
Medical condition: Mieloma múltiple multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) BE (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001399-12 | Sponsor Protocol Number: MORAb-004-203-STS | Start Date*: 2014-01-02 | |||||||||||
Sponsor Name:Morphotek Inc. | |||||||||||||
Full Title: A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma | |||||||||||||
Medical condition: Metastatic Soft Tissue Sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000285-10 | Sponsor Protocol Number: CCS1477-01 | Start Date*: 2021-06-08 |
Sponsor Name:CellCentric Ltd | ||
Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours. | ||
Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC) and other advanced cancers with solid tumours. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020004-30 | Sponsor Protocol Number: A3921080 | Start Date*: 2010-10-05 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS ... | |||||||||||||
Medical condition: Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) SK (Completed) BG (Completed) AT (Completed) PT (Completed) BE (Completed) DK (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004455-36 | Sponsor Protocol Number: NP28673 | Start Date*: 2013-04-11 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT | |||||||||||||
Medical condition: ALK-mutated Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DK (Completed) LU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001285-10 | Sponsor Protocol Number: CA209-171 | Start Date*: 2015-05-15 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at... | |||||||||||||
Medical condition: Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) DE (Completed) FI (Completed) DK (Completed) PT (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) GR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000488-29 | Sponsor Protocol Number: GS-US-236-0118 | Start Date*: 2011-08-02 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000942-36 | Sponsor Protocol Number: IMI2-PainCare-BioPain-RCT1 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processi... | |||||||||||||
Medical condition: Healthy volunteers (intended indication: pain) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001521-43 | Sponsor Protocol Number: 009246QM | Start Date*: 2014-02-20 |
Sponsor Name:Queen Mary University of London | ||
Full Title: A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer | ||
Medical condition: Triple negative (ER-negative, PR-negative/unknown, HER2-negative) advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001264-28 | Sponsor Protocol Number: P2-IMU-838-COV | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022168-11 | Sponsor Protocol Number: TR-701-112 | Start Date*: 2011-03-08 | |||||||||||
Sponsor Name:Trius Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) LV (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002477-56 | Sponsor Protocol Number: IMGN632-0802 | Start Date*: 2020-01-08 | |||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||
Full Title: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia | |||||||||||||
Medical condition: CD123 positive Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000480-87 | Sponsor Protocol Number: GS-US-367-1175 | Start Date*: 2019-06-05 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Chil... | ||||||||||||||||||
Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
